174 related articles for article (PubMed ID: 37401237)
1. Regulation of glucose and glutamine metabolism to overcome cisplatin resistance in intrahepatic cholangiocarcinoma.
Yang SM; Kim J; Lee JY; Lee JS; Lee JM
BMB Rep; 2023 Nov; 56(11):600-605. PubMed ID: 37401237
[TBL] [Abstract][Full Text] [Related]
2. YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation.
Huang CS; Zhu YQ; Xu QC; Chen S; Huang Y; Zhao G; Ni X; Liu B; Zhao W; Yin XY
Clin Transl Med; 2022 Jun; 12(6):e848. PubMed ID: 35696608
[TBL] [Abstract][Full Text] [Related]
3. Combination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinoma.
Cho S; Lee TS; Song IH; Kim AR; Lee YJ; Kim H; Hwang H; Jeong MS; Kang SG; Hong HJ
PLoS One; 2017; 12(2):e0170078. PubMed ID: 28166242
[TBL] [Abstract][Full Text] [Related]
4. Methyltransferase like 3 inhibition limits intrahepatic cholangiocarcinoma metabolic reprogramming and potentiates the efficacy of chemotherapy.
Gao J; Fang Y; Chen J; Tang Z; Tian M; Jiang X; Tao C; Huang R; Zhu G; Qu W; Wu X; Zhou J; Fan J; Liu W; Shi Y
Oncogene; 2023 Aug; 42(33):2507-2520. PubMed ID: 37420030
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment.
Ishimoto U; Kondo S; Ohba A; Sasaki M; Sakamoto Y; Morizane C; Ueno H; Okusaka T
Oncology; 2018; 94(2):72-78. PubMed ID: 29017161
[TBL] [Abstract][Full Text] [Related]
6. Metabolic Phenotyping Predicts Gemcitabine and Cisplatin Chemosensitivity in Patients With Cholangiocarcinoma.
Suksawat M; Phetcharaburanin J; Klanrit P; Namwat N; Khuntikeo N; Titapun A; Jarearnrat A; Vilayhong V; Sa-Ngiamwibool P; Techasen A; Wangwiwatsin A; Mahalapbutr P; Li JV; Loilome W
Front Public Health; 2022; 10():766023. PubMed ID: 35223723
[TBL] [Abstract][Full Text] [Related]
7. H2A.Z regulates tumorigenesis, metastasis and sensitivity to cisplatin in intrahepatic cholangiocarcinoma.
Yang B; Tong R; Liu H; Wu J; Chen D; Xue Z; Ding C; Zhou L; Xie H; Wu J; Zheng S
Int J Oncol; 2018 Apr; 52(4):1235-1245. PubMed ID: 29532867
[TBL] [Abstract][Full Text] [Related]
8. Babaodan overcomes cisplatin resistance in cholangiocarcinoma via inhibiting YAP1.
Li J; Ma X; Xu F; Yan Y; Chen W
Pharm Biol; 2024 Dec; 62(1):314-325. PubMed ID: 38571483
[TBL] [Abstract][Full Text] [Related]
9. Different expression of glucose transporters in the progression of intrahepatic cholangiocarcinoma.
Kubo Y; Aishima S; Tanaka Y; Shindo K; Mizuuchi Y; Abe K; Shirabe K; Maehara Y; Honda H; Oda Y
Hum Pathol; 2014 Aug; 45(8):1610-7. PubMed ID: 24824030
[TBL] [Abstract][Full Text] [Related]
10. Blockade of chloride channel-3 enhances cisplatin sensitivity of cholangiocarcinoma cells though inhibiting autophagy.
Han Y; Zhou Y; Zhou L; Jia X; Yu X; An X; Shi Z
Can J Physiol Pharmacol; 2022 Jul; 100(7):584-593. PubMed ID: 35413227
[TBL] [Abstract][Full Text] [Related]
11. L1 cell adhesion molecule and epidermal growth factor receptor activation confer cisplatin resistance in intrahepatic cholangiocarcinoma cells.
Yoon H; Min JK; Lee DG; Kim DG; Koh SS; Hong HJ
Cancer Lett; 2012 Mar; 316(1):70-6. PubMed ID: 22088438
[TBL] [Abstract][Full Text] [Related]
12. Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma.
Zeng TM; Pan YF; Yuan ZG; Chen DS; Song YJ; Gao Y
Front Immunol; 2022; 13():943066. PubMed ID: 36159865
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of active autophagy induces apoptosis and increases chemosensitivity in cholangiocarcinoma.
Hou YJ; Dong LW; Tan YX; Yang GZ; Pan YF; Li Z; Tang L; Wang M; Wang Q; Wang HY
Lab Invest; 2011 Aug; 91(8):1146-57. PubMed ID: 21647092
[TBL] [Abstract][Full Text] [Related]
14. Targeting PKM2 improves the gemcitabine sensitivity of intrahepatic cholangiocarcinoma cells via inhibiting β-catenin signaling pathway.
Yu W; Zeng F; Xiao Y; Chen L; Qu H; Hong J; Qu C; Cheng G
Chem Biol Interact; 2024 Jan; 387():110816. PubMed ID: 38000456
[TBL] [Abstract][Full Text] [Related]
15. Circular RNA SMARCA5 correlates with favorable clinical tumor features and prognosis, and increases chemotherapy sensitivity in intrahepatic cholangiocarcinoma.
Lu Q; Fang T
J Clin Lab Anal; 2020 Apr; 34(4):e23138. PubMed ID: 31880360
[TBL] [Abstract][Full Text] [Related]
16. Bufalin targeting CAMKK2 inhibits the occurrence and development of intrahepatic cholangiocarcinoma through Wnt/β-catenin signal pathway.
Zhang H; Dong X; Ding X; Liu G; Yang F; Song Q; Sun H; Chen G; Li S; Li Y; Wang M; Guo T; Zhang Z; Li B; Yang L
J Transl Med; 2023 Dec; 21(1):900. PubMed ID: 38082327
[TBL] [Abstract][Full Text] [Related]
17. Screening a redox library identifies the anti-tumor drug Hinokitiol for treating intrahepatic cholangiocarcinoma.
Bai P; Ge C; Yang H; Chen H; Wan L; Zhang Y; Zhang B; Zeng Q; Fan Z; Pei X; Yue W; Yan X
Front Biosci (Landmark Ed); 2022 Jan; 27(1):18. PubMed ID: 35090323
[TBL] [Abstract][Full Text] [Related]
18. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility of cholangiocarcinoma cells to parthenolide-induced apoptosis.
Kim JH; Liu L; Lee SO; Kim YT; You KR; Kim DG
Cancer Res; 2005 Jul; 65(14):6312-20. PubMed ID: 16024633
[TBL] [Abstract][Full Text] [Related]
20. Alpha5 nicotine acetylcholine receptor subunit promotes intrahepatic cholangiocarcinoma metastasis.
Fu Y; Shen K; Wang H; Wang S; Wang X; Zhu L; Zheng Y; Zou T; Ci H; Dong Q; Qin LX
Signal Transduct Target Ther; 2024 Mar; 9(1):63. PubMed ID: 38453934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
